ArticleJournal of cancer research and clinical oncology2026
Expression and clinical significance of cytochrome b561 in endometrial cancer.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo investigate the expression level of cytochrome b561 (CYB561) in endometrial carcinoma tissues and analyze its relationship with clinicopathological characteristics and patient prognosis.
methodsBioinformatic analysis was performed to assess CYB561 mRNA expression and its correlation with prognosis in endometrial cancer. Immunohistochemical staining was used to detect CYB561 protein expression in 195 endometrial carcinoma tissues and 40 adjacent normal endometrial tissues. The associations between CYB561 expression and clinicopathological parameters, as well as its impact on overall survival (OS) and disease-free survival (DFS), were analyzed.
resultsCYB561 expression was significantly higher in endometrial carcinoma tissues compared to adjacent normal tissues (P < 0.001). Low CYB561 expression was significantly associated with advanced FIGO stage (P < 0.05). Moreover, patients with low CYB561 expression exhibited significantly poorer overall survival (OS) and disease-free survival (DFS) (log-rank P < 0.001 for both).
conclusionCYB561 is up-regulated in endometrial carcinoma, and its high expression is associated with a more favorable prognosis, suggesting its potential role as a prognostic biomarker for endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.